Richard Kim, MD, Moffitt Cancer Center

home / authors / richard-kim-md-moffitt-cancer-center

Articles

Richard S. Finn, MD, UCLA Health;Richard Kim, MD, Moffitt Cancer Center;Riad Salem, MD, Northwestern University Feinberg School of Medicine;Amit Singal, MD, UT Southwestern Medical Center

July 24th 2020

mHCC: Influence of PD-L1 Inhibitors on Second-Line Therapy

Richard S. Finn, MD, UCLA Health;Richard Kim, MD, Moffitt Cancer Center;Riad Salem, MD, Northwestern University Feinberg School of Medicine;Amit Singal, MD, UT Southwestern Medical Center

July 24th 2020

ASCO 2020 Data for Treatment of Advanced HCC

Richard S. Finn, MD, UCLA Health;Richard Kim, MD, Moffitt Cancer Center;Riad Salem, MD, Northwestern University Feinberg School of Medicine;Amit Singal, MD, UT Southwestern Medical Center

July 24th 2020

ASCO 2020: HIMALAYA Trial for Advanced HCC

Richard S. Finn, MD, UCLA Health;Richard Kim, MD, Moffitt Cancer Center;Riad Salem, MD, Northwestern University Feinberg School of Medicine;Amit Singal, MD, UT Southwestern Medical Center

July 24th 2020

Role of VEGF TKIs for Treatment of HCC

Richard S. Finn, MD, UCLA Health;Richard Kim, MD, Moffitt Cancer Center;Riad Salem, MD, Northwestern University Feinberg School of Medicine;Amit Singal, MD, UT Southwestern Medical Center

July 24th 2020

Safety of PD-L1 Inhibitors in mHCC

Richard S. Finn, MD, UCLA Health;Richard Kim, MD, Moffitt Cancer Center;Riad Salem, MD, Northwestern University Feinberg School of Medicine;Amit Singal, MD, UT Southwestern Medical Center

July 24th 2020

IMbrave150 Trial: Frontline Treatment of Advanced HCC

Richard S. Finn, MD, UCLA Health;Richard Kim, MD, Moffitt Cancer Center;Riad Salem, MD, Northwestern University Feinberg School of Medicine;Amit Singal, MD, UT Southwestern Medical Center

July 24th 2020

Initiation of Systemic Therapy for mHCC

Richard S. Finn, MD, UCLA Health;Richard Kim, MD, Moffitt Cancer Center;Riad Salem, MD, Northwestern University Feinberg School of Medicine;Amit Singal, MD, UT Southwestern Medical Center

July 24th 2020

Overview and Diagnosis of HCC

Richard S. Finn, MD, UCLA Health;Richard Kim, MD, Moffitt Cancer Center;Riad Salem, MD, Northwestern University Feinberg School of Medicine;Amit Singal, MD, UT Southwestern Medical Center

July 24th 2020

Taletrectinib Yields Durable Responses in TKI Naive and Crizotinib Pretreated ROS1+ NSCLC

Nivolumab/Ipilimumab Bests Nivolumab in Ovarian and Extra-Renal Clear Cell Carcinomas

Trastuzumab Deruxtecan Prolongs PFS in Pretreated HR+, HER2-Low and -Ultralow Metastatic Breast Cancer

Zanidatamab Shows Durable Responses With Longer Follow-up in Pretreated HER2+ Biliary Tract Cancer

View More Latest Conference Coverage

Do Not Sell My Information

Contact Info

2 Commerce Drive
Cranbury, NJ 08512